ICCVAM
This article was originally published in The Rose Sheet
Executive Summary
Federal agencies' responses to recommendations on non-animal test methods for assessing allergic contact dermatitis hazard potential of chemicals is now available, reports the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods. Two test methods recommended to the agencies by ICCVAM were the murine local lymph node assay (LLNA), which uses 20% fewer animals than the original protocol recommended in 1999, and the reduced murine local lymph node assay (rLLNA), which can reduce animal use by 40% compared with the standard LLNA. ICCVAM gave agencies - including FDA, the EPA and the Consumer Product Safety Commission - 180 days to respond to its favorable recommendation for the tests, which comes after consideration of a peer review panel report, public comments and feedback from its Scientific Advisory Committee on Alternative Toxicological Methods (1"The Rose Sheet" Oct. 19, 2009, In Brief)
You may also be interested in...
ICCVAM vouches for rLLNA
The Food and Drug Administration, the Environmental Protection Agency, the Consumer Product Safety Commission and other federal agencies have 180 days to respond to favorable recommendation for the reduced murine local lymph node assay, submitted by the Interagency Coordinating Committee on the Validation of Alternative Methods. Used to assess chemicals' potential to cause allergic contact dermatitis, the rLLNA "is sufficient to distinguish between skin sensitizers and non-sensitizers for testing situations that do not require dose-response information," ICCVAM says. Committee notes that the alternative strategy reduces animal use by 40 percent for each test compared with traditional multi-dose LLNA. ICCVAM's recommendation comes after consideration of a peer review panel report, public comments and feedback from its Scientific Advisory Committee on Alternative Toxicological Methods. The group also has turned over to its member agencies LLNA test method standards for "more efficiently evaluat[ing] the validity of modified test methods that are similar to the traditional LLNA.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.